METABOLIC EFFECTS OF NEWER ANTIPSYCHOTICS IN OLDER PATIENTS

新型抗精神病药对老年患者的代谢影响

• 批准号: 7724925
• 负责人: DILIP V. JESTE
• 金额: $ 14.52万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724925
• 关键词: Antipsychotic Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Metabolic; Quality of life; Research; Research Personnel; Resources; Risk; Risperidone; Source; United States National Institutes of Health; aripiprazole; middle age; olanzapine; older patient; quetiapine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compare the risk of MCCE associated with four atypical agents: aripiprazole, olanzapine, quetiapine, and risperidone in middle aged and elderly patients. Examine the impact of anitpsychotic induced MCCE on everyday functioning and quality of life.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 比较四种非典型药物：阿立哌唑、奥氮平、奎硫平和利培酮在中老年患者中发生MCCE的风险。 检查抗精神病药引起的MCCE对日常功能和生活质量的影响。